MARKETSQUIET
1 hour ago
Allogene Therapeutics, Inc. (ALLO) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases Transcript
SIGNALSMONITORMARKETS
What's happening
SignalsMonitor is following this as a markets story. Seeking Alpha is the outlet attached so far. The first report grouped here was at 9 Nov 2026, 18:41 UTC. The headline in use is “Allogene Therapeutics, Inc. (ALLO) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases Transcript”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
Allogene Therapeutics, Inc. (ALLO) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases Transcript
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by Seeking Alpha
Reported by 1 outlet
- Seeking Alpha